Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.

PubWeight™: 1.30‹?› | Rank: Top 10%

🔗 View Article (PMID 22851267)

Published in J Natl Cancer Inst on July 31, 2012

Authors

Vincent Stanton

Articles citing this

Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J Clin Oncol (2012) 3.61

Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. J Natl Cancer Inst (2013) 3.35

CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther (2013) 3.11

Re: Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. J Natl Cancer Inst (2014) 1.45

Status of adjuvant endocrine therapy for breast cancer. Breast Cancer Res (2014) 1.07

Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer. Br J Clin Pharmacol (2014) 1.06

Pharmacogenomics of breast cancer therapy: an update. Pharmacol Ther (2013) 1.01

Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004-2010. Breast Cancer Res Treat (2012) 0.92

Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol (2014) 0.85

PharmGKB summary: tamoxifen pathway, pharmacokinetics. Pharmacogenet Genomics (2013) 0.85

Variants in tamoxifen metabolizing genes: a case-control study of contralateral breast cancer risk in the WECARE study. Int J Mol Epidemiol Genet (2013) 0.80

Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies. J Natl Cancer Inst (2014) 0.78

Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity. Am J Epidemiol (2016) 0.75